Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease by Geldenhuys, Werner J. et al.
DOI: 10.1002/cbic.201300770
Methyl Yellow: A Potential Drug Scaffold for Parkinson’s
Disease
Werner J. Geldenhuys,*[a] Akiko Kochi,[b] Li Lin,[a] Vijaykumar Sutariya,[c] Dean E. Dluzen,[a]
Cornelis J. Van der Schyf,[d] and Mi Hee Lim*[b, e]
Introduction
Idiopathic Parkinson’s disease (PD) is an age-related neurode-
generative disorder that largely affects patients over the age of
65.[1] In younger patients, the disease has been shown to be
genetically linked.[2] PD largely affects the dopaminergic path-
ways, which ultimately leads to loss of fine motor control. The
loss of these neurons in the substantia nigra yields the classical
motor-associated symptoms of resting tremor, bradykinesia,
and balance impairment.[3] Later stages of the disease are also
correlated with other neurological symptoms, such as demen-
tia and depression.[4] The exact etiology of PD is still unknown,
although it is suggested that environmental factors, such as
pesticide exposure, might play a large role.[5]
One of the causes attributed to the cell death observed in
brains of PD patients is the formation of reactive oxygen spe-
cies (ROS). These ROS originate from several sources, of which
the activity of monoamine oxidases A and B (MAO-A and
MAO-B), bound on the outer membrane of mitochondria, has
been implicated as the major source of ROS production.[6] An
increase in MAO-B enzyme levels in aging patients has been
observed with an increase in loss of dopaminergic neurons,
and the resulting presence of ROS has been indicated as one
of the main apoptotic inducers in neuronal cell death.[6b]
MAO-B inhibitors have been historically used as part of the
pharmacotherapy of PD, in addition to the mainstay therapy of
l-DOPA and a peripheral decarboxylase inhibitor.[7] In addition
to providing symptomatic relief through inhibition of dopa-
mine metabolism,[8] several lines of evidence have suggested
that MAO-B inhibitors are neuroprotective.[9] The significant
role of ROS through MAO-B in PD has led to the development
of several compounds that inhibit MAO-B.[7b,10] Multifunctional
MAO-B compounds (containing inhibitory as well as neuropro-
tective activity) would be useful for treatment if they were
nontoxic and able to penetrate the blood–brain barrier (BBB),
among other favorable drug-like characteristics. With the focus
on these requirements, we initiated a search for compounds
similar to the stilbene framework, for which we previously
showed MAO-B inhibitory activity.[11] The well-studied represen-
tative of this class, resveratrol, has been shown to have several
beneficial effects on mitochondrial dysfunction[12] and in PD
Parkinson’s disease (PD) is an age-related neurodegenerative
disease affecting movement. To date, there are no currently
available therapeutic agents which can prevent or slow disease
progression. Here, we evaluated an azobenzene derivative,
methyl yellow (MY), as a potential drug scaffold for PD; its in-
hibitory activity toward monoamine oxidase B (MAO-B) as well
as drug-like properties were investigated. The inhibitory effect
of MY on MAO activity was determined by a MAO enzyme in-
hibition assay. In addition, the in vitro properties of MY as
a drug candidate (e.g. , blood–brain barrier (BBB) permeability,
serum albumin binding, drug efflux through P-glycoprotein
(P-gp), drug metabolism by P450, and mitochondrial toxicity)
were examined. In vivo effectiveness of MY was also evaluated
in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Par-
kinsonian mouse model. MY selectively inhibited MAO-B in a
dose-dependent and reversible manner. MY was BBB-permea-
ble, bound relatively weakly to serum albumin, was an unlikely
substrate for both systems of P-gp and P450, and did not
cause mitochondrial toxicity. Results from the MPTP Parkinsoni-
an mouse model indicated that, upon treatment with MY, neu-
rotoxicity induced by MPTP was mitigated. Investigations of
MY demonstrate its inhibitory activity toward MAO-B, compli-
ant properties for drug consideration, and its neuroprotective
capability in the MPTP Parkinsonian mouse model. These data
provide insights into potential use, optimization, and new
design of azobenzene derivatives for PD treatment.
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models[,13c] and, as reviewed elsewhere, has led to the develop-
ment of several published compound sets with CNS activity.[14]
Herein, we report the MAO-B inhibitory activity of two small
molecules, azobenzene and methyl yellow (MY; Scheme 1), and
further investigation of MY as a potential drug candidate
through the evaluation of its BBB permeability, drug efficacy
(i.e. , serum albumin binding, elimination through drug efflux/
metabolism), and neuroprotection in a 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) Parkinsonian mouse model.
Results
MAO inhibition
The activity of azobenzene and MY (Scheme 1) toward MAO
inhibition was determined by using recombinant human en-
zymes, as previously described, with minor modifications.[15] As
seen in Table 1, both azobenzene and MY showed abilities to
inhibit the activity of both MAO-A and MAO-B; they appeared
to be selective toward MAO-B over MAO-A to some extent. MY
in particular, was observed to be a potent, relatively selective
MAO-B inhibitor (IC50=ca. 15 nm and 5 mm for MAO-B and
MAO-A, respectively), compared to known inhibitors such as
rasagiline (IC50=14 nm for MAO-B) and safinamide (IC50=
80 nm for MAO-B).[16] In addition, based on time course and Mi-
chaelis–Menten kinetic studies (Figures 1 and 2), MY could be
classified as a reversible inhibitor that acts in a dose-depen-
dent manner.
Molecular docking
In order to gain insight into the binding mode of MY into
MAO-B, ligand docking studies were conducted with
MOE 2011.10, by using a protein structure of MAO-B that was
previously determined with (S)-(+)-2-[4-(fluorobenzyloxy-ami-
no)propionamide] cocrystallized with the gating residue Ile199
in the open position (PDB ID: 2V5Z)[16b] (Figure 4). MY was ob-
served to be oriented with the dimethylamino moiety toward
the flavin adenine dinucleotide (FAD), with the terminal aro-
matic ring spanning the entrance and substrate cavities (Fig-
ure 3A). Potential interaction with the gate residues (Phe168,
Leu171, Ile199, and Tyr326) might have resulted in MY residing
in both cavities (Figure 3B).
Brain uptake studies
The ability of MY to passively diffuse through the BBB was first
evaluated by employing a parallel artificial membrane permea-
bility assay (PAMPA) assay.[17] The permeability value (logPe)
for MY was measured as 4.260.62, compared to the BBB-
permeable compound propranolol (logPe=4.170.39),
thus suggesting that MY could possibly permeate the BBB.
Moving forward, the potential brain uptake of MY was further
evaluated in vivo by determining the concentration of the
compound after treatment in the brain of C57BL/6 mice. MY
was injected intraperitoneally at 1 mgmg1, and its concentra-
tion in the brain was analyzed after 1 h by HPLC (Figure S1).
These results indicated that MY could enter the brain to accu-
mulate at a concentration of ca. 500 nm, which was identified
through a standard curve (r2=0.999).
Scheme 1. Structures of azobenzene ((E)-1,2-diphenyldiazene) and methyl
yellow (MY, (E)-N,N-dimethyl-4-(phenyldiazenyl)aniline).
Table 1. Inhibitory activity of azobenzene and MY toward MAO enzyme
activity in 96-well plate format. Enzyme activity was measured by fluores-
cence following the conversion of nonfluorescent kynuramine to its fluo-
rescent product.
IC50 [mm]
Compound MAO-A MAO-B
azobenzene 22.90.1 2.660.054
MY 4.640.05 0.01460.017
zonisamide[a] 22.611.26
[a] Positive control.[39]
Figure 1. Time–effect experiments on the catalytic activity of MAO-B in the
presence of MY (50 nm). Time points indicate the preincubation of MAO-B
with MY. Enzymatic activity was measured after 20 min incubation with sub-
strate kynuramine (lex=310 nm; lem=380 nm). Data are shown as
meanSD, where n=8.
Figure 2. Effect of MY on the maximal rate of MAO-B activity. The MAO-B
catalytic activity of kynuramine, used as a substrate, in the absence and
presence of 0 (*), 100 (&), 200 (~), 300 (!), and 400 nm (^) MY was deter-
mined as described in the Experimental Section.
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1591 – 1598 1592
CHEMBIOCHEM
FULL PAPERS www.chembiochem.org
Serum albumin binding
The effect of MY on bovine serum albumin (BSA) binding was
investigated by a high-throughput screening (HTS) assay. This
assay measures the degree of fluorescence quenching that
indicates possible ligand binding to either the Sudlow I or II
pocket in BSA.[17a,18] As indicated in Figure 4, MY was observed
to have relatively weak binding toward BSA; binding to BSA
only occurred at higher concentrations (>1 mm), and 50%
binding occurred at approximately 100 mm.
P450 enzyme metabolism
The metabolism of MY was evaluated by using crude murine
liver microsomes (Figure 5). The activity of P450 was deter-
mined by measuring the use of nicotinamide adenine dinucle-
otide phosphate (NADPH) by the enzyme; a decrease in the
fluorescence of NADPH upon addition of compound indicates
metabolic activity.[19] As a positive control, ketoconazole, a
known CYP3A4/5 inhibitor, was used to show that metabolic
activity of P450 decreased upon increasing concentrations of
compound[20] (Figure 5). With the addition of MY, a similar
trend was observed in which the metabolic activity of P450
was reduced (Figure 5), thus implying that this compound
would be an unlikely substrate for P450.
ATPase activity of P-glycoprotein
As P-gp plays an integral role in efflux of xenobiotics from the
brain,[21] a P-gp ATPase assay[22] was performed in order to
identify whether MY is a possible substrate for P-gp. As shown
in Figure 7, MY does not seem to act as a substrate for P-gp, in
comparison to verapamil, a known P-gp substrate.[23]
Mitochondrial membrane potential
In order to assess whether MY could be used for in vivo stud-
ies, mitochondrial toxicity of MY was measured by using an
HTS detection assay[24] (Figure 7). The membrane potential was
compared against trifluorocarbonylcyanide phenylhydrazone
(FCCP), a chemical uncoupler of electron transport and oxida-
tive phosphorylation.[25] FCCP was observed to affect the mem-
Figure 3. Docking studies of MY with MAO-B. The compound was superimposed into the active site of MAO-B bound to the inhibitor safinamide in the crystal
structure (PDB ID: 2V5Z). In the figure, nitrogen, hydrogen, and oxygen atoms are coded as blue, white, and red, respectively. A) Residues within 5  sur-
rounding MY situated at the active site of MAO-B (some omitted for clarity) are divided into entrance cavity (yellow) and substrate cavity (green). The flavin
adenine dinucleotide (FAD) cofactor (gray) is positioned at the outer boundary of the substrate cavity. B) Surface representation of MY, which is surrounded
by the four gate residues and occupies both the entrance and substrate cavities.
Figure 4. Binding of MY to bovine serum albumin (BSA). Serial dilutions of
MY were treated with BSA (final concentration=7.5 mm), and fluorescence
quenching was monitored at lex=280 nm; lem=340 nm.
Figure 5. Effect of MY on P450 metabolism in crude liver microsomes. Meta-
bolic activity of P450 was determined by measurement of NADPH fluores-
cence (lex=340 nm; lem=450 nm) in the presence of A) ketoconazole or
B) MY.
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brane potential in a dose-dependent manner (Figure 7A); how-
ever, treatment with MY did not indicate a loss in membrane
potential (Figure 7B).
Dopamine depletion
The potential of MY as a possible neuroprotective agent was
examined in a Parkinsonian mouse model induced by MPTP,
a neurotoxin precursor to MPP+ , which causes permanent
symptoms of PD.[26] The effect of MY upon striatal dopamine
(DA) loss in the presence of MPTP was evaluated. As observed
in Figure 8, the level of DA was significantly elevated by treat-
ment with MY in the presence of MPTP. This result suggests
that MY could serve as an effective agent for neuroprotection
in PD.
Tyrosine hydroxylase expression
The effect of MY against the loss of tyrosine hydroxylase (TH)
expression in the MPTP mouse model was assessed. The level
of TH was observed to be unaffected in MY-treated mice, com-
pared to that in analogous, compound-free mice (Figure 9).
Furthermore, upon administration of MY, TH concentration was
not shown to be reduced, even in the presence of MPTP,
which significantly decreased protein expression by itself
(Figure 9).
Discussion
MY, an azobenzene derivative with a backbone similar to that
of stilbene, was evaluated as a potential MAO-B inhibitor for
use in PD treatment. Ligands with the stilbene framework have
been previously shown to have MAO-B inhibitory activity.[11]
Moreover, stilbene has been highlighted lately, due to the
Figure 6. Effect of MY on ATPase activity of P-glycoprotein (P-gp). Recom-
binant human P-gp was treated with a solution of drug or vehicle. ATPase
activity was initiated upon addition of reaction buffer and was determined
by the detection of luminescence generated by an ATP-dependent firefly
luciferase reaction.
Figure 7. Evaluation of mitochondria membrane potential in the presence
of varying concentrations of A) trifluorocarbonylcyanide phenylhydrazone
(FCCP) or B) a single concentration of FCCP and MY (10 mm).
Figure 8. Effect of MY toward MPTP-induced striatal dopamine depletion
in the MPTP Parkinsonian mouse model. The experimental details are de-
scribed in the Experimental Section. Each bar represents meanSD, where
n=3–4 mice per group. * Statistical significance P<0.05.
Figure 9.Western blot analysis of striatal tyrosine hydroxylase (TH) protein
expression levels. Groups are 1) vehicle control (DMSO); 2) mice treated with
MPTP; 3) mice treated with both MPTP and MY; 4) mice treated with MY
only. Each bar represents meanSD, where n=3–4 mice per group. * Statis-
tical significance P<0.05.
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myriad of activities demonstrated by resveratrol.[27] Although
resveratrol itself has been shown to be largely devoid of MAO
inhibitory activity,[28] we were able to establish MAO-B inhibi-
tion upon addition of a compound containing the dimethyla-
mino group on the stilbene framework. MY containing a dime-
thylamino group was observed to be a more potent MAO-B in-
hibitor, showing an IC50 value approximately 15 nm lower than
that of azobenzene. In addition, MY presented relative selectivi-
ty (ca. 250-fold) toward MAO-B over MAO-A. Here, MY showed
similar activity to that reported for other dyes .[30] For instance,
methylene blue has been shown to inhibit MAO-B and was
shown to be neuroprotective in an MPTP toxin model.[28] Addi-
tionally, the metabolite of methylene blue, azure B, was shown
to be a much more potent MAO-B inhibitor.[30,31] These dyes,
therefore, might be a rich source of novel MAO-B inhibitors.
In light of MY showing a favorable capability to inhibit
MAO-B, we further characterized the compound as a possible
drug scaffold. A PAMPA assay was first performed to predict
brain distribution potential of MY. The permeability value of
MY suggests that the compound could possibly pass through
the BBB and be distributed into the CNS.[32] Assessing initial
permeability is critical, due to the fact that 98% of CNS drug
clinical trial failures are attributed to poor BBB penetration.[33]
Along with the PAMPA study, initial brain uptake of MY was
investigated in vivo, accumulation of compound at 500 nm 1 h
post-injection into the brain of C5BL/6 mice was indicated, sev-
eral-fold higher than the IC50 required for MAO-B inhibition
(Table 1). Additionally, whether or not the P-gp efflux pump
plays a significant role in the removal of MY from the brain, as
it does with other drugs,[21] was evaluated. As seen in Figure 6,
MY did not act as a substrate for P-gp, as evidenced by the
lack of increased ATP usage associated with an increase in P-
gp activity. This suggests that removal from the brain upon
uptake might occasionally occur. Verapamil was used as posi-
tive control to indicate the effect of a known substrate in our
assay.
Potential drug clearance occurring outside the brain was an-
alyzed. P450 liver enzymes are involved in detoxification,[34]
and in order to determine whether MY could be a substrate
for P450, the metabolism of MY was evaluated by using crude
murine liver microsomes. MY was observed to be an unlikely
substrate for liver P450, implying that when dosed in vivo,
clearance from the bloodstream could be low (Figure 5). Keto-
conazole, a known inhibitor of liver P450 enzymes, is shown as
a positive control. Moreover, MY was shown to bind weakly to
BSA (Figure 4); the concentration of drug in the blood might
therefore be close to therapeutically relevant levels without
the need to increase the dosage.
PD has been associated with mitochondrial dysfunction.[35]
The oxidative stress from dysfunctional mitochondria, as well
as from the inhibition of mitochondrial complex I by MPP+ ,
led us to evaluate the mitochondrial toxicity potential of MY in
vitro. MY did not alter the mitochondrial membrane potential,
indicating that it was safe for use in preclinical models of PD in
vivo. The possible neuroprotective role of MY in vivo (i.e. , the
MPTP Parkinsonian mouse model) was further evaluated. MPTP
is a protoxin that is converted to its toxic pyridinium metabo-
lite MPP+ in astroglia, whereupon it is taken up in the pre-
synaptic terminal through the dopamine transporter.[36] MPP+
itself is a complex I inhibitor that leads to increased generation
of ROS and induces severe dopaminergic cell death.[26b] Upon
injection of MY as a pretreatment before MPTP treatment, the
mice were protected against the neurotoxin, as evidenced by
the mitigation of striatal DA loss as compared to mice treated
with MPTP alone (Figure 8). Protection against DA loss was
also corroborated by the level of TH expression, which is re-
sponsible for catalyzing conversion of the amino acid l-tyro-
sine to l-3,4-dihydroxyphenylalanine (l-DOPA), the precursor
to dopamine.[37] With MY treatment, consistent expression of
TH was observed even in the presence of MPTP, which sup-
presses TH levels, suggesting that MY might aid in increasing
DA levels that are highly reduced in PD-afflicted brains
(Figure 9). Taking into consideration the fact that MY was
shown to be an MAO-B inhibitor, the mechanism of protection
in our in vivo model appeared to be the prevention of a neuro-
toxic pathway: transformation of MPTP to MPP+ . As neurode-
generation is a complex signaling process, an alternative path-
way for protection by MY might also be involved. For instance,
methylene blue is known to interact with the NMDA/iNOS
pathway and thereby provide neuroprotection.[38] Future work
will focus on elucidating these alternative pathways for MY.
Conclusions
PD is a debilitating neurodegenerative disease with no current
therapies that could prevent or reverse the progression of the
disease. Small molecules with multifunctionality (decreasing
ROS production through MAO-B inhibition as well as neuropro-
tective characteristics such as preventing DA loss or preventing
MPP+ generation) have been developed in order to mitigate
toxicity leading to neuronal death. For this work, we evaluated
the novel compound MY and demonstrated its abilities as a po-
tential drug scaffold for MAO-B inhibition with neuroprotective
properties on the basis of in vitro (i.e. , BBB permeability, serum
albumin binding, drug efflux/metabolism, and mitochondrial
toxicity) and in vivo (i.e. , MPTP Parkinsonian mouse model)
studies.
Experimental Section
All reagents were purchased from commercial suppliers and used
as received unless stated otherwise. Azobenzene ((E)-1,2-diphenyl-
diazene) and MY ((E)-N,N-dimethyl-4-(phenyldiazenyl)aniline) were
purchased from Alfa Aesar and Sigma, respectively. Absorbance re-
quired for assays was recorded on either a Synergy 4 plate reader
(BioTek, Winooski, VT) or a Nanodrop UV/Vis spectrophotometer
(Thermo Fisher Scientific). Fluorescence was measured by using
a BioTek Synergy 4 plate reader.
MAO enzyme assays: MAO enzyme inhibition assays were per-
formed by using recombinant human enzyme (BD Genetest, San
Jose, CA) as previously described, with minor modifications.[15] For
the measurement of enzyme activity, kynuramine was employed as
a substrate. As kynuramine is metabolized by MAO, it forms a
fluorescent metabolite 4-hydroxyquinoline (lex=310 nm; lem=
380 nm). The buffer system used was a 0.1m phosphate buffer
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(pH 7.4). The MAO enzyme assays were carried out in a fluorescent
96-well plate. The final concentrations of MAO-A and MAO-B were
6 mgmL1 and 15 mgmL1, respectively. The final concentration of
kynuramine was 40 mm for MAO-A or 20 mm for MAO-B. The com-
pounds (10 mm stock solution in DMSO; less than 2% (v/v) final
concentration of DMSO in the assay) were incubated with MAO
and the substrate for 20 min, after which the reaction was
quenched with the addition of 2n NaOH. IC50 values were deter-
mined by using Prism 5 statistical software (http://www.graphpad.-
com) and calculated from one-site binding, by using eight different
concentrations spanning five log units, each performed in dupli-
cate. Data are reported as the meanSEM, with each drug
screened in duplicate.
Molecular modeling: Docking studies were performed by using
MOE 2011.10 (Chemical Computing Group; http://www.chem-
comp.com). The protein structure (PDB ID: 2V5Z)[16b] of MAO-B was
used in which (S)-(+)-2-[4-(fluorobenzyloxyamino)propionamide]
was cocrystallized, and the gating residue Ile199 was in the open
position. The B chain of MAO-B was deleted, and docking was car-
ried out by using only one of the MAO-B chains. Prior to docking,
the protein was protonated at pH 7.4 to correlate with the enzyme
experiments. The binding site was identified as the area where the
cocrystallized ligand was located. As MOE recognized flavin ade-
nine dinucleotide (FAD) as a part of the ligand set, we first desig-
nated the ligand (S)-(+)-2-[4-(fluorobenzyloxyamino)propionamide]
as such so that MOE could use this to delineate the binding
pocket in the docking run. Only the top-returned binding pose of
the ligand was further evaluated.
Parallel artificial membrane permeability assay: PAMPA experi-
ments were conducted according to previously reported protocols
with slight modifications.[17] A solution of hexadecane in hexane
(5%, v/v) was added to the donor plate containing a polycarbonate
(3 mm) filter membrane and was allowed to sit at room tempera-
ture for 45 min until the hexane evaporated. A solution containing
5% DMSO in phosphate-buffered saline (PBS, pH 7.4) was intro-
duced to each well of the donor plate (150 mL) and acceptor plate
(300 mL). The compounds were added to the donor plate (500 mm
final concentration), and the donor plate was placed on top of the
acceptor plate to form a sandwich. The sandwich was incubated
for 5 h at room temperature. Fluorescence spectra of the solutions
in the acceptor plate were measured at lex/em=360/570 nm. Pro-
pranolol was used as a positive control, with a fluorescent signal at
lex/em=300/338 nm. Each drug was tested in triplicate wells.
Michaelis–Menten enzyme kinetics: The activity of MAO-B was
evaluated in the absence and presence of inhibitor ([inhibitor]=
100, 200, 300, and 400 nm). The enzyme reaction was performed as
mentioned before in a 96-well plate format, with the fluorescence
detected as described previously.[11]
Reversibility study: To determine whether the type of enzyme in-
hibition was reversible or irreversible, MAO-B was preincubated
with MY (50 nm) for set time points (0, 15, 30, 45, and 60 min), at
which time kynuramine was added to start the reaction. The
enzyme reaction was then terminated after 20 min, and the fluo-
rescence intensity was measured as described previously. This
assay was performed in a 96-well black plate (each bar represents
N=8 wells).
Serum albumin binding: Binding of MY to serum albumin was de-
termined by using bovine serum albumin (BSA) as described pre-
viously.[17a,18] Briefly, MY (10 mm stock solution in DMSO) was serial-
ly diluted in a black 96-well plate to give an eight-point data
curve. BSA was added to each well at a final concentration of
7.5 mm. Fluorescence quenching was analyzed at lex/em=280/
340 nm. Each data point was done in triplicate wells.
Metabolism: P450 metabolic studies employing crude liver micro-
somes were carried out as previously described.[19] Mouse livers
(C57BL6/J; Harlan Labs) were perfused with cold PBS (10 mL,
pH 7.4) prior to blood removal. The livers were sliced into smaller
pieces and placed into a Potter homogenizer on ice. Cold Tris
buffer (100 mm, pH 7.4) was added at a volume three times that of
the volume of tissues and homogenized with a Teflon-tipped
pestle (ten strokes). The tissue homogenate was then centrifuged
for 15 min (4 8C, 12000g). The fatty layer was carefully removed,
and the supernatant was saved for the metabolic studies. The pro-
tein concentration was determined by measuring absorbance (A280)
and adjusted to a final concentration of 2 mgmL1. The P450 me-
tabolism assay with liver microsomes was modified to a 96-well
black plate format, conducted in triplicate. Three different concen-
trations of the drug were diluted in Tris buffer (100 mm, pH 7.4),
and an NADPH solution (10 mm) was added to give a final NADPH
concentration of 2 mm. The reaction was initiated upon the
addition of the microsomes to give a final concentration of
0.5 mgmL1 per well. After incubation for 1 h at 37 8C, fluorescence
intensity was analyzed at lex/em=340/450 nm.
P-glycoprotein (P-gp) ATPase assay: A P-gp ATPase assay was
conducted according to a previously published method by using
recombinant protein, with minor modifications.[22] Recombinant
human P-gp expressed in insect cells was purchased (BD Genetest)
for membrane preparation. To test the activity of P-gp ATPase, a so-
lution of drug or vehicle (DMSO) was treated with the membrane
preparation (total of 40 mg protein) in a white clear-bottom 96-well
plate, with each experiment performed in triplicate. Verapamil,
a known substrate of P-gp, was used as a positive control (20 mm
final concentration). The ATPase reaction was initiated with the ad-
dition of reaction buffer (50 mm Tris·MES, 2 mm EDTA, 50 mm KCl,
2 mm dithiothreitol, 5 mm sodium azide, and 2 mm MgATP, pH 6.8)
and incubated in an Eppendorf 96-well plate heater/shaker for
30 min at 37 8C. The reaction was terminated with the addition of
100 mL of a Kinase-Glo solution (Promega). After incubation for
30 min at room temperature, luminescent signal was detected by
using a Synergy 4 plate reader (BioTek). All experiments were car-
ried out in triplicate.
Mitochondrial polarization assay: HTS detection of mitochondrial
toxins was adapted from a previously published method.[24] A
murine neuro-2a (N2a) neuroblastoma cell line was purchased
from ATCC. The N2a cell line was cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Lonza, Walkersville, MD) supplemented
with 10% fetal bovine serum (ATCC), penicillin (100 unitsmL1, Invi-
trogen), and streptomycin (100 mgmL1; Hyclone, Logan, UT). The
cells were grown and maintained at 37 8C with 5% CO2. The cells
(50000 cells per well) were seeded into a 96-well black clear-
bottom plate and allowed to adhere overnight. The medium was
removed, and a solution containing either MY or trifluorocarbonyl-
cyanide phenylhydrazone (FCCP, 50 mL, various concentrations) was
added to each well, triplicate wells were used for each group. Tet-
ramethylrhodamine methyl ester (TMRM) was added to each well
at a final concentration of 50 nm. The plates were incubated for
30 min at 37 8C. After incubation, a brilliant black solution
(15 mgmL1, 20 mL) was added, and fluorescence was detected
(lex=540/535 nm; lem=620/640 nm).
Western blot: Brain tissue samples were homogenized in cold lysis
buffer (tenfold wet weight) containing protease inhibitors and phe-
nylmethanesulfonylfluoride (PMSF). Homogenized brain tissue was
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centrifuged for 15 min (14000g, 4 8C). Protein in the supernatant
was quantified by using a Pierce BCA protein assay kit (Thermo Sci-
entific). Each sample containing 10 mg of protein was separated by
using a 4–12% Bio-Rad miniProtean precast gel (200 V, 35 min).
The protein was transferred onto a PVDF membrane (100 V, 1 h)
and blocked for 1 h with 5% nonfat dry milk blocking solution in
0.2% TBST. The membrane was treated with a rabbit polyclonal
anti-TH antibody (1:1000, Millipore) in TBST overnight at 4 8C and
probed with a horseradish peroxidase-conjugated anti-rabbit sec-
ondary antibody (1:3000, Invitrogen) in TBST for 1 h. Each blot was
then exposed to the Pierce ECL substrate and read on a Protein M
chemiluminescent detector (http://www.proteinsimple.com).
Brain distribution: C57BL/6 mice were injected with MY
(1 mgmg1) and, after 1 h, the brain was removed after a short
(30 s) perfusion with PBS pH 7.4 to remove any residual drug from
the brain vasculature. The brains were weighed, and three volumes
of PBS were added. The tissue was homogenized by using a
Dounce tissue homogenizer (pestles A and B), with at least four
strokes each. Acetonitrile (CH3CN) was then added, and the sam-
ples were mixed by vortexing. The samples were centrifuged for
10 min (10000g, 4 8C). The CH3CN fraction was used for HPLC anal-
ysis. A PerkinElmer HPLC was used, with a Thermo Hypersil-Key-
stone BioBasic-C18 column (5 mm 2504.6 mm), and the column
temperature set at 20 8C. The mobile phase consisted of 75%
CH3CN/25% H2O, and the flow rate was 1 mLmin
1. The detection
wavelength was set at 305 nm. An isocratic gradient was used.
Four mice were used for the determination of brain distribution.
Neurochemical assay: Adult male C57BL/6 retired breeder mice
were housed individually, had free access to food and water, and
were maintained under a 12 h light cycle with lights on at 06:00.
All treatments complied with the NIH guide for Care and Treat-
ment of Laboratory Animals and were approved by the IACUC at
NEOMED. All efforts were made to minimize animal suffering, to
reduce the number of animals used, and to utilize alternatives to
in vivo techniques when possible. Mice were treated with either
1) vehicle control (DMSO), 2) MPTP (35 mgkg1 interperitoneal (i.p.)
injection), 3) MPTP (35 mgkg1 i.p.) and MY (1 mgkg1 i.p.), or
4) MY (1 mgkg1. i.p.). MY was given 30 min before MPTP treat-
ments. MY was dissolved in DMSO and injected at 1 mLg of mouse.
At day 7 post-MPTP treatment, the brain was dissected to remove
the striatum for HPLC analysis of DA content. For determinations
of striatal tissue levels of DA, the tissue was weighed and placed in
cold HClO4 (0.1n, 500 mL, 4 8C). These tissue samples were sonicat-
ed and centrifuged; an aliquot was removed to measure DA and
3,4-dihydroxyphenylacetic acid (DOPAC). Tissue samples were eval-
uated for DA content by HPLC with electrochemical detection. Bio-
genic amines were separated on a Supelco column (Discovery C18,
10 cm3 mm5 mm). Samples were injected into a 20 mL loop. A
degassed isogradient mobile phase consisting of sodium acetate
(50 mm), citric acid (27.4 mm), NaOH (10 mm), sodium octyl sulfate
(0.1 mm), EDTA (0.1 mm), and 5% MeOH in filtered deionized water
was used for the system. The mobile phase was adjusted to a final
pH of 4.5 with the addition of NaOH and filtered (0.45 mm, Milli-
pore filter) prior to use. Standards were diluted in perchloric acid
(0.1n) in increments of 3.1, 6.2, 12.5, 25, 50, 100, 200, and 400 pg/
20 mL. Samples were analyzed by using the ESA 501 program. The
assay sensitivity (6.2–12.5 pg/20 mL) was determined by the obser-
vation of reliable peaks above baseline noise.
Statistical analysis: Statistical analysis was performed by using a
one-way ANOVA and Tukey’s post-hoc test with InStat (Graphpad)
statistical software. Statistical significance was considered when
p<0.05. Data are shown here as meanSEM, where the number
of animals was four to five per treatment group.
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